Current CRS management after CAR T therapy mainly relies on the blocking IL-6 with tocilizumab (recombinant humanized anti-human IL-6 receptor monoclonal antibody), which is FDA approved to treat CRS. The gene discussed is IL6; the disease is congenital rubella syndrome.